European Diabetes Market

2 Min Read

Europe ranks second behind the United States in terms of the largest market for diabetes management therapies and products. One reason for the rise of diabetes in Europe is attributed to its aging population, which lends to a higher prevalence of abnormal glucose tolerance in the adult population. In 2010, roughly 33% of the European population as a whole was older than 50 years, a percentage that is expected to surpass 40% by 2030.

Europe ranks second behind the United States in terms of the largest market for diabetes management therapies and products. One reason for the rise of diabetes in Europe is attributed to its aging population, which lends to a higher prevalence of abnormal glucose tolerance in the adult population. In 2010, roughly 33% of the European population as a whole was older than 50 years, a percentage that is expected to surpass 40% by 2030.

Like most global markets, diabetes in Europe is dominated by sales of insulin, test strips and anti-diabetic drugs.  Significant growth is expected in novel technologies like continuous blood glucose monitors and integrated pumps/monitors (eventually, “artificial pancreas” products), but the existing market is still very dominated by well established diabetes products.

Source: MedMarket Diligence, LLC; Report #D510.

TAGGED:
Share This Article
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Exit mobile version